Medicenna Therapeutics Corp. has released a corporate presentation outlining its current pipeline and upcoming clinical milestones. The presentation highlights the advancement of MDNA11, a next-generation IL-2 immunotherapy, which is being evaluated as both a monotherapy and in combination with checkpoint inhibitors for the treatment of solid tumors. The ABILITY-1 Phase 1⁄2 basket study is ongoing, with plans for a registrational trial in checkpoint refractory cancers. Additionally, the NEO-CYT Phase 1b study will assess MDNA11 in neoadjuvant melanoma, with initial data readouts anticipated in the second half of 2026. The company is also progressing MDNA113, a bifunctional PD-1 x IL-2 fusion protein, towards first-in-human trials in late 2026, and is developing candidates targeting autoimmune and inflammatory diseases. Bizaxofusp (MDNA55), intended for recurrent glioblastoma, is positioned as a phase 3-ready asset with orphan drug and fast track designations. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

Medicenna Therapeutics Unveils Pipeline Update on Immunotherapy Advances for Cancer and Autoimmune Diseases